SEEBRI BREEZHALER (GLYCOPYRRONIUM) - RAPID ONSET OF ACTION, HIGHLY SELECTIVE TO M3 RECEPTORS, LONG ACTING INHALED ANTICHOLINERGIC FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Glikopironium bromide (glycopyrronium) - rapid onset of action, highly selective to M3 receptors, long acting inhaled anticholinergic bronchodilator for the treatment of chronic obstructive pulmonary disease. It is dry-powder, once-daily used medication, approved for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrronium has rapid onset of action – its bronchodilation effect starts within 5 minutes after the first dose inhalation. Bronchodilation effect of glycopyrronium sustains 24-hours and does not diminish using this medication continually for a long time. Glycopyrronium is effective, safe and well tolerated as the only known long-acting anticholinergic, tiotropium bromide. Glycopyrronium significantly reduced moderate and severe COPD exacerbation rate and the use of short acting rescue medication. Once daily used glycopyrronium (Seebri Breezhaler) could be a new choice for the treatment of patients with COPD.